2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - Hall E
Chimeric Antigen Receptor T cell therapies have transformed the outcomes of patients with relapsed and refractory multiple myeloma and its role continues to expand at a rapid pace. This session brings together cutting edge data spanning novel CAR-T constructs, emerging targets beyond BCMA and next-generation platforms designed to improve efficacy and durability.  Presenters will explore how these advances are reshaping treatment paradigms from heavily pretreated myeloma to earlier integration and newly diagnosed treatment settings as the field pushes towards deeper and more durable responses.  Attendees will get insights into latest clinical trial results in this innovative session.
Technology and Procedures, Gene Editing, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

119 Anti-BCMA CAR T-cell therapy followed by autologous stem cell transplantation and a second CAR T infusion in newly diagnosed multiple myeloma with TP53 abnormalities: A phase 2 trial

Yuntong Liu, Jian Cui, MD, PhD2, Lihui Shi3, Hesong Zou4, Weiwei Sui5, Lu-Gui Qiu, PhD6, Gang An, MD7
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
3 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
5 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
6 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
7 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China

Background: Patients with newly diagnosed multiple myeloma (NDMM) harboring TP53 abnormalities remain at high risk of early relapse despite intensive frontline therapy. We designed a sequential strategy comprising BCMA-directed CAR T-cell infusion (CAR T1), autologous stem cell transplantation (ASCT), and a second CAR T-cell infusion (CAR T2) to integrate complementary mechanisms: CAR T1 for rapid immune-mediated cytoreduction, high-dose melphalan/ASCT for non-cross-resistant eradication of residual disease, and CAR T2 to renew BCMA-directed immune pressure during post-transplant lymphopenic immune reconstitution, potentially clearing residual myeloma cells in the graft or bone marrow and establishing immune surveillance.

 

Methods: This prospective, single-center, single-arm phase 2 trial (NCT05850286) enrolled transplant-eligible patients aged 18-65 years with NDMM and del(17p) and/or TP53 mutation. After 3-4 cycles of VRd-based induction, patients underwent separate collections for CAR T-cell manufacturing and ASCT. Patients received lymphodepletion and CAR T1, followed by consolidation. High-dose melphalan (200 mg/m²) and ASCT were followed by CAR T2 on day +2 or +3; lenalidomide-based maintenance began approximately day +100. The primary endpoint was complete response rate (CRR). Measurable residual disease (MRD) was assessed by next-generation flow (NGF, sensitivity <10-5). Data cutoff was April 15, 2026.

 

Results: Twenty-two patients were enrolled; 20 received CAR T1, 18 underwent ASCT, and 16 received CAR T2. In the infused cohort (n = 20), median age was 59 years (range, 40-65), and 55.0% were male; 95.0% had del(17p), 37.5% of patients had TP53 mutation, 31.3% had biallelic TP53 inactivation and 80.0% had double-hit cytogenetics. CAR T1 markedly deepened response: CRR increased from 45.0% after induction to 80.0% at 3 months after CAR T1, while NGF-MRD negativity increased from 35.0% to 95.0%. At 3 months after ASCT/CAR T2, CRR was 94.4% (17/18) and NGF-MRD negativity was 82.4% (14/17). All 20 infused patients achieved stringent complete response and NGF-MRD negativity as their best response. After a median follow-up of 23.4 months (range, 7.5-35.2), 3 patients had progressed and no deaths had occurred. Median progression-free survival (PFS) and overall survival were not reached; estimated 24-month PFS was 87.1% (95% CI, 71.8%-100.0%). Cytokine release syndrome occurred in 45.0% after CAR T1 and 37.5% after CAR T2; all events were grade 1 or 2. No immune effector cell-associated neurotoxicity syndrome, grade ≥3 CRS, or treatment-related deaths occurred. CAR transgene expansion was detected after both infusions, with median Cmax values of 55,807 and 9,713 copies/µg genomic DNA after CAR T1 and CAR T2, respectively.

 

Conclusion: In transplant-eligible NDMM with TP53 abnormalities, the CAR T1-ASCT-CAR T2 strategy produced rapid and deep responses, with all infused patients achieving sCR and NGF-MRD negativity as their best response. The estimated 24-month PFS was 87.1%, and toxicity was manageable. These findings support the feasibility and preliminary activity of integrating sequential BCMA-directed CAR T-cell therapy with ASCT and warrant confirmation in larger, controlled multicenter studies.

Yuntong Liu: No relevant conflicts of interest to declare.